Home › Kanser sa Pantog › Oklahoma › Oklahoma City
Pag-aaral pangklinika para sa Kanser sa Pantog sa Oklahoma City, OK
Isang pag-aaral para sa Kanser sa Pantog ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Oklahoma City. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
The Vanguard Study: Testing a New Way to Screen for Cancer
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Nagre-recruitPhase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
Nagre-recruitPhase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Mercy Hospital Oklahoma City, Oklahoma City
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Nagre-recruitPhase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Nagre-recruitPhase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Nagre-recruitPhase 1
- University of Oklahoma - Health Sciences Center, Oklahoma City
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Nagre-recruitPhase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Nagre-recruitPhase 2
- OU Health Stephenson Cancer Center, Oklahoma City
- OU Medical Center, Oklahoma City
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Nagre-recruitPhase 1
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
Nagre-recruitObservasyonal na pag-aaral
- Mercy Hospital - OKC, Oklahoma City
Pag-aaral para sa Kanser sa Pantog sa ibang lungsod
- New York City, NY35 pag-aaral
- Nashville, TN31 pag-aaral
- Houston, TX31 pag-aaral
- Dallas, TX27 pag-aaral
- Washington, DC26 pag-aaral
- Boston, MA26 pag-aaral
- Baltimore, MD24 pag-aaral
- Los Angeles, CA24 pag-aaral
- St. Louis, MO22 pag-aaral
- Seattle, WA21 pag-aaral
- Chicago, IL21 pag-aaral
- Philadelphia, PA21 pag-aaral
Iba pang pag-aaral sa Oklahoma City
- Non-Small Cell Lung Cancer28 pag-aaral
- Kanser sa Ovary28 pag-aaral
- Kanser ng Endometrium25 pag-aaral
- Colorectal Cancer22 pag-aaral
- Kanser sa Prostate21 pag-aaral
- Kanser sa Baga19 pag-aaral
- Kanser sa Suso17 pag-aaral
- Metastatic Cancer16 pag-aaral
- Kanser (lahat ng uri)14 pag-aaral
- Acute Myeloid Leukemia14 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg13 pag-aaral
- Kanser sa Pancreas11 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.